Takeda (TAK) Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection

Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection (Refractory, With or Without Resistance

More Than Three Times as Many Transplant Recipients With Confirmed Resistant Cytomegalovirus (CMV) Infection at Baseline Receiving the Investigational Drug Maribavir Achieved CMV Viremia Clearance Compared to Conventional Antiviral Therapies, Building on Previously Presented Results Supporting the Efficacy of Maribavir

Transplant Recipients Receiving Maribavir Experienced Lower Rates of Treatment-Related Neutropenia and Acute Kidney Injury Compared to Conventional Antiviral Therapies

Takeda Continues to Investigate Maribavir for the First-Line Treatment of CMV in Hematopoietic Cell Transplant Recipients in an Ongoing Phase 3 Clinical Trial

OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited... More